A civil court trial was the ending result of unethical business research in 2012 for a pharmaceutical company. GlaxoSmithKline (GSK) is a pharmaceutical company that used unethical research practices to obtain greater success. GSK produces numerous prescription drugs used for different psychological disorders. According to the official United States’ Complaint for the case, “from 1999 through 2010 in some instances, GSK engaged in fraudulent scheme to deceive and defraud physicians, patients, regulators, and federal health care programs to cause prescribing and payment for certain of GSK’s drugs” (U.S. v GlaxoSmithKline, 2011). The drugs Paxil, Wellbutrin, Advair, Imitrex, Lotronex, Flovent, Valtrex, Lamictal, and Zofran are some of the drug names involved with the trial (Belkin, 2013). What makes the research performed by GSK unethical is the fact that results were manipulated or not reported for certain drugs they produced. GSK then promoted uses of the drugs that were “off-label,” or not intended or approved. In addition, the company would pay kickbacks to physicians for prescribing the drugs. GSK also made false and misleading statements concerning the drug Avandia and its safety risks to consumers. As if these practices were not bad enough, the company also reported false “best prices” which allowed an
References: Belkin, M. (2013, October). GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data. Health Impact News Daily,. U.S. v GSK (2011), United States Complaint, CA No. 11-10398-rwz